HK Stock Market Move | Cstone Pharma-B (02616) rose nearly 5% before the close of trading. The global multi-center phase I clinical trial of CS5007 has been launched, and executive shareholdings increase demonstrate confidence in development.

CSTONE PHARMA-B (02616) rose by nearly 5% in the final trading session, as of the time of writing, it is up by 4.26%, trading at 4.65 Hong Kong dollars, with a turnover of 36.4976 million Hong Kong dollars. In terms of news, CStone Pharma announced that the global multicenter Phase I clinical trial of the company's pipeline 2.0 core candidate drug CS5007 (EGFR/HER3 bispecific antibody-drug conjugate [ADC]) has officially received approval from the Australian Human Research Ethics Committee (HREC). This not only marks the full global clinical development of CS5007, but also signifies that the company's Pipeline 2.0 strategy is accelerating its implementation, with subsequent significant forces entering the clinical fast lane, providing lasting confidence for medium-to-long term growth. It is worth noting that CStone Pharma has recently received support from several directors to increase their holdings. Jefferies indicated that the company's management and board of directors plan to increase their holdings of the company's stock, fully illustrating the high confidence of the management in the progress of the pipeline BD. The management stated that the current stock price is severely undervalued and remains optimistic about the progress of CS2009 licensing negotiations. Data disclosed by the company at the 2026 ASCO shows that CS2009 has demonstrated solid efficacy and excellent safety in non-small cell lung cancer and various cold tumors, and is expected to become the next-generation cornerstone immunotherapy with the best potential.